Teresa Rafferty

801 total citations
18 papers, 595 citations indexed

About

Teresa Rafferty is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, Teresa Rafferty has authored 18 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Rheumatology and 6 papers in Hematology. Recurrent topics in Teresa Rafferty's work include Selenium in Biological Systems (6 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (6 papers). Teresa Rafferty is often cited by papers focused on Selenium in Biological Systems (6 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (6 papers). Teresa Rafferty collaborates with scholars based in United Kingdom, United States and Germany. Teresa Rafferty's co-authors include Geoffrey J. Beckett, Roderick C. McKenzie, John Hunter, Roddie C. McKenzie, Fergus Nicol, John R. Arthur, A. Forbes Howie, C. C. Walker, Hagop M. Kantarjian and Francis J. Giles and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical Journal.

In The Last Decade

Teresa Rafferty

18 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Teresa Rafferty United Kingdom 13 286 104 100 89 76 18 595
A. Cordier Switzerland 14 34 0.1× 212 2.0× 89 0.9× 130 1.5× 71 0.9× 30 713
Sara Balesaria United Kingdom 15 214 0.7× 165 1.6× 97 1.0× 156 1.8× 90 1.2× 19 678
AK Black Thailand 9 64 0.2× 76 0.7× 11 0.1× 32 0.4× 36 0.5× 14 558
Yukina Nishito Japan 12 435 1.5× 101 1.0× 231 2.3× 125 1.4× 9 0.1× 16 610
Michelle Lewin United Kingdom 7 190 0.7× 170 1.6× 59 0.6× 9 0.1× 21 0.3× 8 472
Ariëtte M. van Bennekum United States 18 140 0.5× 490 4.7× 63 0.6× 20 0.2× 7 0.1× 20 883
N.J. de Fouw Netherlands 14 222 0.8× 70 0.7× 8 0.1× 169 1.9× 31 0.4× 17 636
A. Giménez Spain 14 106 0.4× 159 1.5× 27 0.3× 16 0.2× 12 0.2× 33 860
Zhijie Jian China 12 185 0.6× 222 2.1× 142 1.4× 16 0.2× 6 0.1× 25 706
Bruce R. Bacon United States 10 254 0.9× 108 1.0× 82 0.8× 150 1.7× 83 1.1× 11 504

Countries citing papers authored by Teresa Rafferty

Since Specialization
Citations

This map shows the geographic impact of Teresa Rafferty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Rafferty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Rafferty more than expected).

Fields of papers citing papers by Teresa Rafferty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Rafferty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Rafferty. The network helps show where Teresa Rafferty may publish in the future.

Co-authorship network of co-authors of Teresa Rafferty

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Rafferty. A scholar is included among the top collaborators of Teresa Rafferty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Rafferty. Teresa Rafferty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Winer, Eric P., Sara M. Tolaney, Hovav Nechushtan, et al.. (2012). Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 535–535. 15 indexed citations
2.
Gordon, Michael, Nicholas J. Vogelzang, Patrick Schöffski, et al.. (2011). Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3010–3010. 47 indexed citations
3.
Alexander-Sefre, Farhad, Robert J. B. Nibbs, Teresa Rafferty, et al.. (2009). Clinical Value of Immunohistochemically Detected Lymphatic and Vascular Invasions in Clinically Staged Endometrioid Endometrial Cancer. International Journal of Gynecological Cancer. 19(6). 1074–1079. 20 indexed citations
4.
Schatz, Michael, Norbert Gattermann, Oliver G. Ottmann, et al.. (2006). A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). Journal of Clinical Oncology. 24(18_suppl). 6588–6588. 2 indexed citations
5.
6.
Coutre, Philipp D. le, Oliver G. Ottmann, Richard A. Larson, et al.. (2006). A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). Journal of Clinical Oncology. 24(18_suppl). 6531–6531. 12 indexed citations
7.
8.
Kantarjian, Hagop M., Norbert Gattermann, Andreas Hochhaus, et al.. (2006). A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).. Blood. 108(11). 2169–2169. 18 indexed citations
9.
Coutre, Philipp le, Andreas Hochhaus, Dominik Heim, et al.. (2006). A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES).. Blood. 108(11). 4912–4912. 5 indexed citations
10.
Hochhaus, Andreas, Oliver G. Ottmann, Timothy P. Hughes, et al.. (2006). A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.. Blood. 108(11). 2703–2703. 14 indexed citations
11.
12.
Rafferty, Teresa, Mary Norval, Ali A. El‐Ghorr, et al.. (2003). Dietary Selenium Levels Determine Epidermal Langerhans Cell Numbers in Mice. Biological Trace Element Research. 92(2). 161–172. 11 indexed citations
13.
Rafferty, Teresa, M.H.L. Green, Jillian E. Lowe, et al.. (2003). Effects of selenium compounds on induction of DNA damage by broadband ultraviolet radiation in human keratinocytes. British Journal of Dermatology. 148(5). 1001–1009. 44 indexed citations
14.
Rafferty, Teresa, et al.. (2003). Selenium protects primary human keratinocytes from apoptosis induced by exposure to ultraviolet radiation. Clinical and Experimental Dermatology. 28(3). 294–300. 26 indexed citations
15.
Rafferty, Teresa, C. C. Walker, John Hunter, Geoffrey J. Beckett, & Roddie C. McKenzie. (2002). Inhibition of ultraviolet B radiation-induced interleukin 10 expression in murine keratinocytes by selenium compounds. British Journal of Dermatology. 146(3). 485–489. 18 indexed citations
16.
Żak-Prelich, Małgorzata, Mary Norval, Thomas J. Venner, et al.. (2001). cis-Urocanic Acid does not Induce the Expression of Immunosuppressive Cytokines in Murine Keratinocytes¶†. Photochemistry and Photobiology. 73(3). 238–238. 14 indexed citations
17.
Rafferty, Teresa, Roderick C. McKenzie, John Hunter, et al.. (1998). Differential expression of selenoproteins by human skin cells and protection by selenium from UVB-radiation-induced cell death. Biochemical Journal. 332(1). 231–236. 69 indexed citations
18.
McKenzie, Roderick C., Teresa Rafferty, & Geoffrey J. Beckett. (1998). Selenium: an essential element for immune function. Immunology Today. 19(8). 342–345. 236 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Cordier Breakdown of academic impact, for papers by Sara Balesaria Breakdown of academic impact, for papers by AK Black Breakdown of academic impact, for papers by Yukina Nishito Breakdown of academic impact, for papers by Michelle Lewin Breakdown of academic impact, for papers by Ariëtte M. van Bennekum Breakdown of academic impact, for papers by N.J. de Fouw Breakdown of academic impact, for papers by A. Giménez Breakdown of academic impact, for papers by Zhijie Jian Breakdown of academic impact, for papers by Bruce R. Bacon
Rankless by CCL
2026